Fernandez-Penas, P., Carlino, M., Tsai, K., Atkinson, V., Shaheen, M., Thomas, S., Mihalcioiu, C., Hagen, T. V., Roberts-Thomson, R., Haydon, A., Mant, A., Butler, M., Daniels, G., Buchbinder, E., Hyngstrom, J., Moller, M., Puzanov, I., Lance Cowey, C., Whitman, E., Ballesteros-Merino, C., Jensen, S., Fox, B., Schmidt, E., Krepler, C., Diede, S., Browning, E., Hermiz, R., Svenson, L., Salazar, J., Lee, J., Baker, C., Bannavong, D., Sell, J., Foerter, K. M., Canton, D., Aung, S., Twitty, C., Algazi, A., & Daud, A. (n.d.). 799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data. Journal for immunotherapy of cancer, 8, A477–A478. http://access.bl.uk/ark:/81055/vdc_100144731873.0x000005